Please login to the form below

Not currently logged in
Email:
Password:

Profil Institute appoints former Amylin CEO

Dan Bradbury joins board of diabetes company

The Profil Institute for Clinical Research has appointed Dan Bradbury to its board of directors.

Bradbury is an experienced figure in the life science industry, serving as CEO of Amylin from 2007 to 2012 until its acquisition by Bristol-Myers Squibb.

He is currently a managing member of the life sciences consultancy firm BioBrit.

Dr Marcus Hompesch, CEO of diabetes-focused Profil Institute said: “Dan Bradbury is a highly regarded and prominent leader in the global pharmaceutical industry.”

He added: “With Mr Bradbury's considerable experience in driving strategic growth, I am certain that he will bring tremendous insight and guidance to help further shape the company's strategic course.”

7th November 2013

From: Research, Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare focused, award-winning video production company which operates in the US and Europe....

Latest intelligence

EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...

Infographics